REG - Avacta Group PLC - Block Listing - Application to AIM

AvactaAnnouncement

Today 15:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260601:nRSA5122Ga&default-theme=true

RNS Number : 5122G  Avacta Group PLC  01 June 2026

Avacta Group plc

 

Block Listing Application to AIM

 

LONDON and PHILADELPHIA - June 1, 2026 - Avacta Therapeutics (AIM: AVCT, "the
Company", "Avacta"), a clinical stage biopharmaceutical company developing
pre|CISION(®), a tumor-activated oncology delivery platform, today announces
an application has been made to AIM for a block listing of 5,500,000 ordinary
shares of 10 pence each in the Company ("Ordinary Shares"). This will be used
to facilitate the admission of shares to trading following the exercise of
options granted under the Group's LTIP/ESOS Scheme.

 

The Ordinary Shares will be issued from time to time pursuant to the Company's
existing plans including outstanding options already issued but not yet
exercised to the employees of the Company. New Ordinary Shares issued
following option exercises and admitted to trading under the block admission
will rank pari passu in all respects with the existing Ordinary Shares.

 

The block listing is expected to become effective on 2 June 2026. The Company
will continue to make six-monthly announcements of the utilisation of the
block admission, in line with its obligations under AIM Rule 29.

 

At the time of this announcement, Avacta has 457,892,574 Ordinary Shares in
issue. This figure may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

-Ends-

 

For further information from Avacta, please contact:

 

 Avacta Group plc                                   https://avacta.com/ (https://avacta.com/)

 Christina Coughlin, Chief Executive Officer        via Cohesion Bureau

 Strand Hanson Limited (Nominated Adviser)          www.strandhanson.co.uk (http://www.strandhanson.co.uk)

 James Harris / Chris Raggett / James Dance

 Zeus (Broker)                                      www.zeuscapital.co.uk (http://www.zeuscapital.co.uk)

 James Hornigold / George Duxberry / Dominic King

 Cohesion Bureau                                    avacta@cohesionbureau.com (mailto:avacta@cohesionbureau.com)

 Communications / Media / Investors

 Richard Jarvis

About Avacta - https://avacta.com/ (https://avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies through its proprietary pre|CISION(®)
platform. pre|CISION(®) is a payload delivery system based on a
tumor-specific protease (fibroblast activation protein or FAP) that is
designed to concentrate highly potent payloads in the tumor microenvironment
while sparing normal tissues. Avacta's innovative pre|CISION(®) peptide drug
conjugates (PDCs) leverage this tumor-specific release mechanism to provide
unique benefits over traditional antibody drug conjugates, releasing active
payload in the tumor and reducing systemic exposure and toxicity and allowing
dosing to be optimized to deliver the best outcomes for patients.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFBMJTMTBMBJF



            Copyright 2019 Regulatory News Service, all rights reserved